VTGN
NSCVistagen Therapeutics Inc.
Healthcare•Biotechnology
Watchlists:
Last updated: Wednesday 16th July 2025
2.25
-0.13 (-5.46%)
Prev Close:2.38
Open:2.38
Bid:2.27
Ask:2.43
52 Week Range
1.904.01
Volume:191,521
Mkt Cap:66 M
46
MarketXLS Rank ®
Hold
Price Target
$2.59
+15.1%
Financials
Financial Statements
VTGN - Cash Flow (Annual)
| Mar-25 | Mar-24 | Mar-23 | Mar-22 | Mar-21 | Mar-20 | Mar-19 | Mar-18 | Mar-17 | Mar-16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| (increase) Decrease In Other Current Assets | 90500.0 | 146300.0 | ||||||||
| (increase) Decrease In Other Current Liabilities | -412000.0 | 516000.0 | 206000.0 | -2 M | 4 M | |||||
| (increase) Decrease In Other Working Capital | 190000.0 | |||||||||
| (increase) Decrease In Payables | 6 M | 522000.0 | -934000.0 | 2 M | 51000.0 | -390700.0 | 1 M | 541700.0 | -451700.0 | -547200.0 |
| (increase) Decrease In Receivables | -40600.0 | 300000.0 | -300000.0 | |||||||
| Amortization Of Intangibles | 105900.0 | 510800.0 | ||||||||
| Capital Expenditure Reported | 528000.0 | 200400.0 | 275400.0 | 174000.0 | 1600.0 | 239100.0 | 26300.0 | |||
| Cash At Beginning Of Period | 68 M | 103 M | 1 M | 13 M | 10 M | 3 M | 428500.0 | 70000.0 | ||
| Cash At End Of Period | -55 M | 67 M | 17 M | 68 M | 1 M | 1 M | 13 M | 10 M | 3 M | 428500.0 |
| Cash Flow | -42 M | -26 M | -50 M | -46 M | -12 M | -16 M | -15 M | -9 M | -7 M | -5 M |
| Cash Flow From Continuing Investing Activities | -13 M | -61000.0 | -740000.0 | -200400.0 | -275400.0 | -174000.0 | -1600.0 | -239100.0 | -26300.0 | |
| Change In Account Payable | 6 M | 522000.0 | -934000.0 | 2 M | 51000.0 | -390700.0 | 1 M | 541700.0 | -451700.0 | -547200.0 |
| Change In Payables And Accrued Expense | 6 M | 522000.0 | -934000.0 | 2 M | 51000.0 | -390700.0 | 1 M | 541700.0 | -451700.0 | -547200.0 |
| Change In Prepaid Assets | -88000.0 | 250000.0 | 3 M | -2 M | -328400.0 | 182600.0 | 589000.0 | 131200.0 | -227700.0 | 25700.0 |
| Change In Working Capital | 5 M | 1 M | 2 M | -2 M | 3 M | 91900.0 | 2 M | 819200.0 | -679400.0 | -521500.0 |
| Depreciation | 130000.0 | 153500.0 | 117600.0 | 103100.0 | 91200.0 | 80700.0 | 54900.0 | 53500.0 | ||
| Depreciation Unreconciled | 635000.0 | 568000.0 | 532000.0 | 711100.0 | 477600.0 | 544400.0 | 602000.0 | 80700.0 | 138600.0 | 590800.0 |
| Depreciation And Amortization | 532000.0 | 711100.0 | 477600.0 | 544400.0 | 602000.0 | 80700.0 | 138600.0 | 590800.0 | ||
| Financing Cash Flow | 3 M | 128 M | -1 M | 10 M | 114 M | 4 M | 17 M | 17 M | 10 M | 5 M |
| Free Cash Flow | -42 M | -26 M | -50 M | -45 M | -12 M | -16 M | -15 M | -9 M | -8 M | -5 M |
| Gain Loss On Sale Of PPE | 6000.0 | 2300.0 | ||||||||
| Income Tax Paid Supplemental Data | 3400.0 | 2600.0 | 2600.0 | 2600.0 | 2400.0 | 2400.0 | 2400.0 | |||
| Interest Paid Supplemental Data | 300.0 | 13300.0 | 14800.0 | 8000.0 | 8900.0 | 16600.0 | 12700.0 | |||
| Issuance Of Capital Stock | 93 M | 16 M | 4 M | 17 M | 17 M | 10 M | 280000.0 | |||
| Issuance Of Debt | -985000.0 | -1 M | -378700.0 | -293600.0 | -220500.0 | -203000.0 | -182200.0 | -111500.0 | ||
| Issuance Of Capital Stock | 93 M | 16 M | 4 M | 17 M | 17 M | 10 M | 280000.0 | |||
| Issuance Of Debt | -985000.0 | -1 M | -3000.0 | -382000.0 | -296600.0 | -223200.0 | -205400.0 | -183500.0 | -112500.0 | |
| Net Cash From Financing Activities | 3 M | 128 M | -1 M | 6 M | 113 M | 4 M | 17 M | 17 M | 10 M | 5 M |
| Net Cash From Investing Activities | -13 M | -61000.0 | -740000.0 | -200400.0 | -275400.0 | -174000.0 | -1600.0 | -239100.0 | -26300.0 | |
| Net Cash From Operating Activities | -42 M | -26 M | -50 M | -45 M | -12 M | -16 M | -15 M | -9 M | -7 M | -5 M |
| Net Change In Cash & Cash Equivalents | -52 M | 103 M | -51 M | -35 M | 102 M | -12 M | 3 M | 7 M | 2 M | 358500.0 |
| Net Income From Continuing Operations | -51 M | -29 M | -59 M | -48 M | -18 M | -21 M | -25 M | -14 M | -10 M | -47 M |
| Net Common Stock Issuance | 93 M | 16 M | 4 M | 17 M | 17 M | 10 M | 280000.0 | |||
| Net Foreign Currency Exchange Gain Loss | -6400.0 | |||||||||
| Net Investment Properties Purchase And Sale | -13 M | -212000.0 | -200400.0 | |||||||
| Net Investment Purchase And Sale | -13 M | -212000.0 | -200400.0 | |||||||
| Net Issuance Payments Of Debt | -985000.0 | -1 M | -3000.0 | -382000.0 | -296600.0 | -223200.0 | -205400.0 | -183500.0 | -112500.0 | |
| Net Long Term Debt Issuance | -1500.0 | -3000.0 | -3300.0 | -3000.0 | -2700.0 | -2400.0 | -1300.0 | -1000.0 | ||
| Net PPE Purchase And Sale | -528000.0 | -200400.0 | -275400.0 | -174000.0 | -1600.0 | -239100.0 | -26300.0 | |||
| Net Preferred Stock Issuance | 94 M | 278000.0 | 5 M | |||||||
| Operating (gains) Losses | 6000.0 | 22700.0 | 135000.0 | 27 M | ||||||
| Other Financing Charges Net | 6 M | 6 M | ||||||||
| Other Investing Changes Net | -212000.0 | -200400.0 | ||||||||
| Other Non-cash Items | 4 M | 2 M | 7 M | 3 M | 2 M | 4 M | 8 M | 4 M | 4 M | 16 M |
| Preferred Stock Issuance | 94 M | 278000.0 | 5 M | |||||||
| Proceeds From Issuance Of Warrants | 239400.0 | 13 M | 710000.0 | 605700.0 | ||||||
| Proceeds From Stock Option Exercised | 104000.0 | 139900.0 | ||||||||
| Purchase Of Float Term Investments | -25 M | |||||||||
| Purchase Of Property Plant & Equipment | -528000.0 | -200400.0 | -275400.0 | -174000.0 | -1600.0 | -239100.0 | -26300.0 | |||
| Purchase Of Investment | -25 M | |||||||||
| Purchase Of PPE | -528000.0 | -200400.0 | -275400.0 | -174000.0 | -1600.0 | -239100.0 | -26300.0 | |||
| Repayment Of Debt | -1500.0 | -3000.0 | -3300.0 | -3000.0 | -2700.0 | -2400.0 | -1300.0 | -1000.0 | ||
| Repayment Of Debt | -985000.0 | -1 M | -3000.0 | -606400.0 | -296600.0 | -223200.0 | -205400.0 | -183500.0 | -112500.0 | |
| Revenue Per Share | 402000.0 | 557600.0 | 360000.0 | 441300.0 | 510800.0 | 146300.0 | 83700.0 | 537300.0 | ||
| Sale Of Short Term Investments | 12 M | |||||||||
| Sale Of Investment | 12 M | |||||||||
| Short Term Debt Issuance | 224400.0 | |||||||||
| Short Term Debt Payments | -985000.0 | -1 M | -603100.0 | -293600.0 | -220500.0 | -203000.0 | -182200.0 | -111500.0 | ||
| Stock Based Compensation | 4 M | 2 M | 3 M | 3 M | 2 M | 4 M | 3 M | 2 M | 851300.0 | 4 M |
| Unrealized Gain Loss On Investment Securities | 78000.0 |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.